Samjin Lorazepam designated exit-prevention drug, saving ₩20 billion annually
AI Summary- Ministry of Health and Welfare designated Samjin Lorazepam as an exit-prevention pharmaceutical.
- 20 billion Korean won in annual fiscal savings is expected from managing Samjin Lorazepam.
- Holoxan and Endoxan will receive price adjustments reflecting their actual costs.